Inmune Bio Inc. (INMB)
NASDAQ (CM) NASDAQ (CM) Primary Summary
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Q2 Earnings Call Highlights
INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027.
Inmune Bio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 585 | $661 | $1,111.5 | $450.5 | 68.15% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2,000 | $2,560 | $4,170 | $1,610 | 62.89% |
 Point72 Asset Management LP Point72 Asset Management LP | 16,577 | $21,218.56 | $35,972.09 | $14,753.53 | 69.53% |
 Jeffery Yorg Focus Partners Advisor Solutions LLC | 43,556 | $118,175.14 | $82,756.4 | -$35,418.74 | -29.97% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 9 | $10.17 | $15.75 | $5.58 | 54.87% |
Inmune Bio Inc. (INMB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inmune Bio Inc. ever had a stock split?
Inmune Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | David J. Moss CEO | NASDAQ (CM) Exchange | 45782T105 CUSIP |
| US Country | 21 Employees | - Last Dividend | - Last Split | 4 Feb 2019 IPO Date |
Overview
INmune Bio, Inc. is a clinical-stage immunology company based in the United States, dedicated to reprogramming the innate immune system to combat diseases. Established in 2015 and with its headquarters in Boca Raton, Florida, INmune Bio focuses on the development and commercialization of innovative therapeutic products aimed at the treatment of hematologic malignancies, solid tumors, and chronic inflammation. The company's approach involves leveraging the body's own immune system, aiming to offer novel treatments for patients with unmet medical needs. Through strategic license agreements with entities such as Xencor, Inc., Immune Ventures, LLC, and the University of Pittsburgh, INmune Bio is poised to advance its research and development initiatives in the field of immunotherapy.
Products and Services
- INKmune - Currently in Phase 1 clinical trials, INKmune is a promising therapy tailored for patients with high-risk myelodysplastic syndrome. This treatment is designed to enhance the patient's immune system to effectively identify and combat malignant cells.
- INB03 - INB03 is advancing through pre-clinical studies for its potential to counteract certain types of cancer that are resistant to conventional immunotherapies. Specifically, it is targeted towards cancers that express MUC4, a mucinous polyglucan that has been associated with resistance to immunotherapy treatments. This includes forms of HER2+ breast cancer and other cancers that express MUC4 and exhibit resistance to existing treatments.
- XPro1595 - XPro1595 represents INmune Bio's venture into the treatment of neuroinflammatory diseases, focusing on Alzheimer's disease and Treatment Resistant Depression (TRD). By targeting a novel aspect of the immune system related to inflammation, this drug candidate aims to provide relief and potentially modify the course of these debilitating conditions.
